Key facts
- BioGraph 55’s last known valuation is $25.0M.
- It has raised $20.1M; the latest was Later Stage VC ($11.8M) in Jun 2024.
- Notable investors include University of California, Pfizer Ventures, Red Tree Venture Capital, Panacea Venture, Los Angeles — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for BioGraph 55
- ·The full record, as it builds
Funding rounds
No funding rounds for BioGraph 55 are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BioGraph 55
Developer of novel B-cell therapies and drugs designed to address significant unmet clinical needs of autoimmunity. The company offers discovering and developing bispecific antibodies for immuno-oncology and another for autoimmunity that utilizes a reverse translational approach and identifies potential cellular targets within diseased tissues and validates mechanisms, enabling healthcare professionals to capture clinically relevant content from the tumor microenvironment.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2014
- Employees
- 4
- Website
- biograph55.com/
- Ownership
- Privately Held (backing)
BioGraph 55 doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BioGraph 55 shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BioGraph 55 in its N-PORT filings yet. We sweep new filings monthly.